SynriboActive Ingredient(s): Omacetaxine Mepesuccinate
FDA Approved: * October 26, 2012
Pharm Company: * IVAX PHARMS
Omacetaxine mepesuccinate (INN, trade names Synribo ), formerly named as homoharringtonine or HHT, is a pharmaceutical drug substance that is indicated for treatment of chronic myeloid leukemia (CML). HHT is a natural plant alkaloid derived from Cephalotaxus fortunei. HHT and related compound esters of cephalotaxine were described first in 1970, and were the subject of intensive research efforts by Chinese investigators to clarify their role as anticancer and antileukemic agents from the 1970... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.
Synribo 3.5 mg/ml Subcutaneous Injection, Powder, Lyophilized, for SolutionNDC: 63459-177
give details of Synribo .In Which Disease Synribo Is Used...